dc.contributor.author | Kalyoncu, Umut | |
dc.contributor.author | Pehlivan, Yavuz | |
dc.contributor.author | Akar, Servet | |
dc.contributor.author | Kaşifoğlu, Timuçin | |
dc.contributor.author | Kimyon, G. | |
dc.contributor.author | Karadağ, Ö. | |
dc.contributor.author | Kiraz, Sedat | |
dc.contributor.author | Mercan, Rıdvan | |
dc.date.accessioned | 2022-05-11T14:05:02Z | |
dc.date.available | 2022-05-11T14:05:02Z | |
dc.date.issued | 2021 | |
dc.identifier.issn | 1300-0144 | |
dc.identifier.uri | https://doi.org/10.3906/sag-2012-5 | |
dc.identifier.uri | https://hdl.handle.net/20.500.11776/4875 | |
dc.description.abstract | Background/aim: To evaluate treatment adherence and predictors of drug discontinuation among patients with inflammatory arthritis receiving bDMARDs within the first 100 days after the announcement of the COVID-19 pandemic. Materials and methods: A total of 1871 patients recorded in TReasure registry for whom advanced therapy was prescribed for rheumatoid arthritis (RA) or spondyloarthritis (SpA) within the 3 months (6–9 months for rituximab) before the declaration of COVID-19 pandemic were evaluated, and 1394 (74.5%) responded to the phone survey. Patients’ data regarding demographic, clinical characteristics and disease activity before the pandemic were recorded. The patients were inquired about the diagnosis of COVID-19, the rate of continuation on bDMARDs, the reasons for treatment discontinuation, if any, and the current general disease activity (visual analog scale, [VAS]). Results: A total of 1394 patients (493 RA [47.3% on anti-TNF] patients and 901 SpA [90.0% on anti-TNF] patients) were included in the study. Overall, 2.8% of the patients had symptoms suggesting COVID-19, and 2 (0.15%) patients had PCR-confirmed COVID-19. Overall, 18.1% of all patients (13.8% of the RA and 20.5% of the SpA; p = 0.003) discontinued their bDMARDs. In the SpA group, the patients who discontinued bDMARDs were younger (40 [21–73] vs. 44 years [20–79]; p = 0.005) and had higher general disease activity; however, no difference was relevant for RA patients. Conclusion: Although the COVID-19 was quite uncommon in the first 100 days of the pandemic, nearly one-fifth of the patients discontinued bDMARDs within this period. The long-term effects of the pandemic should be monitored. © TÜBİTAK. | en_US |
dc.description.sponsorship | This study was funded by Hacettepe Rheumatology Society. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | Turkiye Klinikleri | en_US |
dc.identifier.doi | 10.3906/sag-2012-5 | |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.subject | Biologic DMARDs | en_US |
dc.subject | COVID-19 | en_US |
dc.subject | Rheumatoid arthritis | en_US |
dc.subject | Spondyloarthritis | en_US |
dc.subject | abatacept | en_US |
dc.subject | adalimumab | en_US |
dc.subject | certolizumab pegol | en_US |
dc.subject | disease modifying antirheumatic drug | en_US |
dc.subject | etanercept | en_US |
dc.subject | golimumab | en_US |
dc.subject | hydroxychloroquine | en_US |
dc.subject | infliximab | en_US |
dc.subject | leflunomide | en_US |
dc.subject | methotrexate | en_US |
dc.subject | rituximab | en_US |
dc.subject | salazosulfapyridine | en_US |
dc.subject | secukinumab | en_US |
dc.subject | tocilizumab | en_US |
dc.subject | antirheumatic agent | en_US |
dc.subject | adult | en_US |
dc.subject | aged | en_US |
dc.subject | Ankylosing Spondylitis Disease Activity Score | en_US |
dc.subject | Article | en_US |
dc.subject | Bath ankylosing spondylitis disease activity index | en_US |
dc.subject | Bath ankylosing spondylitis functional index | en_US |
dc.subject | cohort analysis | en_US |
dc.subject | coronavirus disease 2019 | en_US |
dc.subject | Crohn Disease Activity Index | en_US |
dc.subject | DAS28 | en_US |
dc.subject | disease activity | en_US |
dc.subject | drug withdrawal | en_US |
dc.subject | erythrocyte sedimentation rate | en_US |
dc.subject | female | en_US |
dc.subject | Health Assessment Questionnaire | en_US |
dc.subject | health status | en_US |
dc.subject | human | en_US |
dc.subject | major clinical study | en_US |
dc.subject | male | en_US |
dc.subject | observational study | en_US |
dc.subject | pandemic | en_US |
dc.subject | polymerase chain reaction | en_US |
dc.subject | prospective study | en_US |
dc.subject | questionnaire | en_US |
dc.subject | remission | en_US |
dc.subject | rheumatoid arthritis | en_US |
dc.subject | Simplified Disease Activity Index | en_US |
dc.subject | spondylarthritis | en_US |
dc.subject | visual analog scale | en_US |
dc.subject | adolescent | en_US |
dc.subject | medication compliance | en_US |
dc.subject | middle aged | en_US |
dc.subject | pandemic | en_US |
dc.subject | register | en_US |
dc.subject | rheumatoid arthritis | en_US |
dc.subject | very elderly | en_US |
dc.subject | young adult | en_US |
dc.subject | Adolescent | en_US |
dc.subject | Adult | en_US |
dc.subject | Aged | en_US |
dc.subject | Aged, 80 and over | en_US |
dc.subject | Antirheumatic Agents | en_US |
dc.subject | Arthritis, Rheumatoid | en_US |
dc.subject | Cohort Studies | en_US |
dc.subject | COVID-19 | en_US |
dc.subject | Female | en_US |
dc.subject | Humans | en_US |
dc.subject | Male | en_US |
dc.subject | Medication Adherence | en_US |
dc.subject | Middle Aged | en_US |
dc.subject | Pandemics | en_US |
dc.subject | Prospective Studies | en_US |
dc.subject | Registries | en_US |
dc.subject | SARS-CoV-2 | en_US |
dc.subject | Young Adult | en_US |
dc.title | Preferences of inflammatory arthritis patients for biological disease-modifying antirheumatic drugs in the first 100 days of the COVID-19 pandemic | en_US |
dc.title.alternative | Preferences of inflammatory arthritis patients for biological disease-modifying antirheumatic drugs in the first 100 days of the covid-19 pandemic | en_US |
dc.type | article | en_US |
dc.relation.ispartof | Turkish Journal of Medical Sciences | en_US |
dc.department | Fakülteler, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı | en_US |
dc.identifier.volume | 51 | en_US |
dc.identifier.issue | 4 | en_US |
dc.identifier.startpage | 1615 | en_US |
dc.identifier.endpage | 1623 | en_US |
dc.institutionauthor | Mercan, Rıdvan | |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.authorscopusid | 12794831300 | |
dc.authorscopusid | 13205593600 | |
dc.authorscopusid | 7004438602 | |
dc.authorscopusid | 8392501600 | |
dc.authorscopusid | 55542843700 | |
dc.authorscopusid | 14630767100 | |
dc.authorscopusid | 6506739457 | |
dc.identifier.wos | WOS:000691544700002 | en_US |
dc.identifier.scopus | 2-s2.0-85114289836 | en_US |
dc.identifier.pmid | 33611869 | en_US |